The latest news: NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Unfortunately, this reports that the combination of treatments mentioned did not work as well as hoped. Dedifferentiation—Turning Back the Cellular Clock Interesting article... talks about how the different subtypes of glioblastomas may have different cells of origin - so may need personalized treatment. IBTA E NEWS JANUARY 2013 This is from our friends at the IBTA The Cancer Support Community is conducting a new survey to help develop educational materials and programs Our friends at The Cancer Support Community needs our help - they want you to fill out a survey about the needs of families dealing with a brain tumor. Please take the time to fill out this survey! Thanks